TWST

Twist Bioscience Corp. (TWST) - 10-K Summary

Business Context and Reporting Period

This summary covers the Annual Report on Form 10-K for Twist Bioscience Corporation for the fiscal year ended September 30, 2025. Twist is a leading synthetic biology company that utilizes a proprietary silicon-based platform to manufacture synthetic DNA, RNA, and proteins. The company serves over 3,800 customers globally across healthcare, chemicals/materials, academic research, and food/agriculture sectors. In May 2025, the company spun out its DNA data storage business into a new independent entity, Atlas Data Storage, Inc.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 20% year-over-year, driven primarily by a $39.0 million increase in NGS tools revenue and a $20.9 million increase in synthetic genes revenue.
• Margin Expansion: Gross margin improved significantly to 50.7% from 42.6%, attributed to revenue growth, flat fixed manufacturing costs, and process improvements.
• Profitability Improvement: Net loss narrowed substantially to $77.7 million from $208.7 million. This was aided by a $48.8 million gain on the sale of the DNA data storage business and a reduction in operating expenses.
• Expense Management: Research and Development (R&D) expenses decreased 12% to $80.3 million, largely due to the divestiture of the data storage business. Conversely, Selling, General, and Administrative (SG&A) expenses increased 13% to $247.0 million, driven by higher stock-based compensation and personnel costs.
• Asset Impairment: Unlike the prior year, which included a $44.9 million impairment charge related to Biopharma assets, no impairment charges were recorded in fiscal 2025.

Outlook, Risks, and Unusual Items

• Strategic Divestiture: The company completed the spin-out of its DNA data storage business to Atlas Data Storage in May 2025, receiving equity, cash, and a promissory note. This transaction generated a $48.8 million gain.
• Liquidity and Financing: In October 2024, the company entered a Royalty Purchase Agreement with XOMA Royalty, receiving $15.0 million upfront in exchange for 50% of future milestone and royalty payments from specific antibody discovery agreements. Management believes current cash and investments are sufficient to fund operations for at least 12 months.
• Profitability Path: The company continues to incur net losses and has an accumulated deficit of $1.32 billion. Future profitability depends on scaling revenue, managing growth costs, and leveraging the Wilsonville, Oregon manufacturing facility.
• Key Risks:
  • Customer Concentration: While no single customer accounted for >10% of revenue, the company relies on a limited number of large customers.
  • Supply Chain: Dependence on a single-source supplier for a critical component of the DNA synthesis process.
  • Regulatory: Potential changes in FDA regulations regarding Laboratory Developed Tests (LDTs) and evolving international trade controls.
  • Competition: Intense competition in synthetic biology and NGS markets from established players and new entrants.

Investor Verification Checklist

• Revenue Quality: Verify the sustainability of the 20% revenue growth and the mix between recurring NGS tools sales versus one-time biopharma service contracts.
• Cash Burn Rate: Assess the trajectory of operating cash flow usage ($47.6 million in FY2025) against the current cash balance ($232.4 million total liquid assets) to determine runway without additional financing.
• Atlas Investment: Review the valuation and terms of the equity stake in Atlas Data Storage ($53.9 million recorded investment) and the potential for future milestone payments.
• Stock-Based Compensation: Monitor the impact of increasing stock-based compensation ($64.5 million in FY2025) on future operating margins as the company scales.
• Manufacturing Capacity: Confirm the utilization rates and scalability of the Wilsonville, Oregon facility, which is central to the company's cost-reduction strategy.